PFE Stock Recent News
PFE LATEST HEADLINES
Pfizer, yielding 5.6%, is an Ultra SWAN bargain with upside potential in the next year. Despite $70 billion in debt, Pfizer's A- credit rating and stable cash flow ensure long-term stability and very strong dividend safety. Pfizer's growth outlook includes a 5% long-term growth rate, with a 10% to 11% long-term return potential.
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Evan David Seigerman, BMO Biotech Analyst, joins 'Closing Bell Overtime' to talk Pfizer shares climbing on activist firm Starboard taking a stake in the company.
Pharmaceutical giant Pfizer (PFE) is seeing stock gains in Monday's pre-market trading after activist investor Starboard Value took up a $1 billion stake, according to a Wall Street Journal report. Yahoo Finance senior health reporter Anjalee Khemlani covers Starboard's reported investment in Pfizer as the pharma company seeks to reposition itself coming out of the COVID-19 pandemic.
Pfizer (PFE, Financial) stock saw a notable increase of 2.94% attributed to a reported $1 billion investment by activist investor Starboard Value. This strategic move is intended to breathe new life into Pfizer, as the stock has experienced a substantial decrease from its highs during the pandemic era.
Can Starboard Value and former CEO Ian Read save Pfizer stock?
Pfizer stock popped Monday on a report activist investor Starboard Value took a roughly $1 billion stake in the struggling drugmaker.
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Media reports indicate that activist investor Starboard Value has acquired approximately $1 billion worth of shares in Pfizer (PFE, Financial). Following this news, Pfizer's stock rose nearly 3% in pre-market trading.
Pfizer Inc. NYSE: PFE hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE NASDAQ: BNTX sent shares surging up to $61.71 in December 2021, driven by its COVID-19 vaccine sales. Since then, it's been downhill for the medical sector giant as COVID revenues dried up with the pandemic in the rearview mirror.